BrainSigns

BrainSigns operates at the intersection of neuroscience research, biosignal analytics, specialist consulting, and digital health. Its position is differentiated by combining several modalities—EEG, eye tracking, galvanic skin response, photoplethysmography, implicit association testing, and virtual reality—rather than focusing on a single wearable or a single clinical measurement. The company also connects measurement hardware, synchronized recording, and interpretation through BS Reader, a real-time neurometrics engine, and the Mindtooth platform. This creates a broader research and applied-evaluation offering than a conventional EEG equipment provider, while its use cases span human factors, aviation workload, consumer research, clinical assessment, and operational vigilance. Relative to larger neurotechnology companies, BrainSigns appears more specialized and research-led, with an emphasis on customized studies and domain expertise rather than mass-market hardware.

BrainSigns has followed a research-to-application trajectory since its founding in July 2010. The €2 million grant announced on Oct 22, 2015 provided a documented financing milestone and involved EISMEA and the European Commission. Over time, the company expanded from recording and analyzing brain and other biosignals into integrated products and services covering workload evaluation, neuromarketing, clinical applications, and immersive research environments. The clearest inflection point is 2022, when BrainSigns reported completing the Mindtooth EEG System with its Neurometrics App at TRL8–9. That milestone indicates movement toward deployable real-time monitoring of stress, workload, and vigilance, particularly for specialized operators and other controlled environments. Current scale remains modest: the company is classified in the 1–10 employee range and has four highlighted current positions, including research and development, marketing communications, and two co-founder-led roles. A vacancies page indicates ongoing hiring activity, but there is no quantified employee-growth series, later financing, acquisition, or additional round publicly documented.